Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2018 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Rate of Corticosteroid-Induced Mood Changes in Patients with Inflammatory Bowel Disease: A Prospective Study.
Ou G, Bressler B, Galorport C, Lam E, Ko HH, Enns R, Telford J, Schaffer N, Lee T, Rosenfeld G. Ou G, et al. J Can Assoc Gastroenterol. 2018 Sep;1(3):99-106. doi: 10.1093/jcag/gwy023. Epub 2018 Jun 4. J Can Assoc Gastroenterol. 2018. PMID: 31294728 Free PMC article.
Participants completed validated questionnaires (Beck Depression Inventory-II and Activation Subscale of Internal State Scale version two) before starting prednisone, after two weeks of prednisone, and at the end of prednisone taper to assess for mood changes. Harvey-Brads …
Participants completed validated questionnaires (Beck Depression Inventory-II and Activation Subscale of Internal State Scale version two) b …
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ; Precise 3 Study Investigators. Lichtenstein GR, et al. Clin Gastroenterol Hepatol. 2010 Jul;8(7):600-9. doi: 10.1016/j.cgh.2010.01.014. Epub 2010 Feb 1. Clin Gastroenterol Hepatol. 2010. PMID: 20117244 Clinical Trial.
We assessed the long-term efficacy, safety, and immunogenicity of continuous versus interrupted maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn's disease. METHODS: Patients who responded to induction therapy at week 6 of the PEGylated Antibo …
We assessed the long-term efficacy, safety, and immunogenicity of continuous versus interrupted maintenance therapy with subcutaneous certol …